NCM · Biotechnology

PHIO (PHIO) Stock

$1.04 -1.89% NCM: PHIO Healthcare

Valuation

MetricValue
Price$1.04
Market Cap$12.08M
P/E Ratio-1.73
P/B Ratio0.62
P/S Ratio0.00
EPS (TTM)$-0.62
52-Week High$4.19
52-Week Low$0.81
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-69.95%
ROA-42.33%
ROCE-45.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio66.93

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-14.0M$-11.0M$-11.0M$-7.0M$-9.0M
Net Profit$-13.0M$-11.0M$-11.0M$-7.0M$-9.0M
EPS$-111.32$-89.61$-46.76$-0.91$-1.45
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$25.0M$13.0M$9.0M$6.0M$21.0M
Total Liabilities$3.0M$2.0M$2.0M$1.0M$1.0M
Cash$24.0M$12.0M$8.0M$5.0M$21.0M
Borrowings$0$0$0$0$0

Latest News

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series TMX Newsfile · Jul 22, 2026 Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series TMX Newsfile · Jul 22, 2026 Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors TMX Newsfile · Jul 21, 2026 Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones InvestorsHub · Jul 15, 2026 Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision TMX Newsfile · Jul 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-12.0M$-11.0M$-7.0M$-8.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$2.0M$0$0$0$0
Net Cash Flow$10.0M$-12.0M$-3.0M$-3.0M$16.0M
Free Cash Flow$-12.0M$-12.0M$-11.0M$-7.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-84.63%
Quick Ratio66.93
Interest Coverage—
Return 1Y-62.60%
Return 3Y-96.38%
Return 5Y-99.55%

Ownership

Insiders Held1.93%
Institutions Held10.81%
Institutions Float Held11.03%
Institutional HolderSharesReport Date
Geode Capital Management, LLC147,2542026-03-31
Jane Street Group, LLC119,1892026-03-31
Vanguard Capital Management LLC79,8532026-03-31
Cetera Investment Advisers45,0002026-03-31
Vanguard Fiduciary Trust Co38,1692026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
APRE $0.62 -1.16% -0.47 $4.06M 0.00%
APVO $4.21 -4.10% -0.06 $9.21M 0.00%
BCDABioCardia, Inc. $0.84 -1.11% -0.83 $4.88M 0.00%
CELZ $0.79 -2.09% -1.47 $2.05M 0.00%

About PHIO

PHIO is led by CEO Robert J. Bitterman, employs 5 people, headquartered in US, publicly traded since 2012.

PHIO stock trades at $1.04 with a market capitalization of $12.08M. The stock is valued at a price-to-earnings (P/E) ratio of -1.73, price-to-book of 0.62, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.81 and $4.19, and currently trades 75.2% below its 52-week high.

On profitability, PHIO generates a return on equity (ROE) of -69.95%, return on capital employed of -45.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides